In trials, patients who had at least 50% scalp hair loss for more than six months who ... and other drugs in the class including Pfizer's Xeljanz (tofacitinib) and AbbVie's Rinvoq (upadacitinib).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback